目的: 探究北京市某三级医院集采和国谈药品协同管理的实践成效,为推动医院合理用药、完善医院药品管理提供建议。方法: 利用Excel软件,采用对比分析法探究医院2017年—2021年的药品采购数据。结果: 协同管理后,集采和国谈药品占医院总药品目录品规的比重提高了4.35倍,集采中标药品采购数量占比提高了4.59倍,国谈药品采购频次提高了6.21倍,药品采购总金额下降了0.5亿元。结论: 集采和国谈药品协同管理提高了药品可及性和医保基金使用效率、推动了医院合理用药、优化了医院药品采购供应管理。
Abstract
Objective: The paper attempts to explore the effect of collaborative drug management in a tertiary hospital in Beijing, to provide suggestions for promoting rational drug use, improving drug management in hospitals. Methods: Excel software was used to explore the drug purchase data of the hospital from2017to2021by comparative analysis. Results: After collaborative management, the proportion of centralized procurement, national negotiation drugs in the total drug catalog of the hospital increased4.35times, the proportion of selected centralized procurement drugs quantity increased4.59times, the frequency of national negotiation drug procurement increased6.21times, the total amount of drug procurement decreased50million yuan. Conclusion: The coordinated drug management of centralized purchase, national negotiation can improve the availability of drugs, the efficiency of medical insurance funds, promote rational drug use in hospitals, optimize the drug purchase, supply management in hospitals
关键词
国家组织药品集中采购 /
国家医保谈判 /
协同管理
Key words
national centralized drug procurement /
national medical insurance negotiation /
cooperative management
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 张晓利. 集采+国谈:扩面前行格局嬗变[J].中国医院院长,2021,17(24):2.
[2] 国务院办公厅.关于印发国家组织药品集中采购和使用试点方案的通知:国办发〔2019〕2号[EB/OL].(2019-01-17)[2022-08-10] .http://www.gov.cn/zhengce/content/2019-01/17/content_5358604.htm.
[3] 于晓彦,蔡锦洪,何春辉,等."三医"联动政策背景下国家药品价格谈判的现状[J].广西医学,2019,41(19):4.
[4] 人力资源社会保障部.关于将36种药品纳入国家基本医疗保险、工伤保险和生育保险药品目录乙类范围的通知:人社部发〔2017〕54号[EB/OL].(2017-07-13)[2022-08-10] .http://www.mohrss.gov.cn/SYrlzyhshbzb/shehuibaozhang/zcwj/yiliao/201707/t20170718_274153.html.
[5] 北京市医疗保障局.关于执行第一,二,四批国家组织药品集中采购和京津冀药品联合带量采购等中选结果有关事项的通知:京医保发〔2021〕1号[EB/OL].(2021-05-21)[2022-08-10] .http://www.beijing.gov.cn/zhengce/zhengcefagui/202107/t20210714_2436478.html.
[6] 国务院办公厅.关于印发"十四五"全民医疗保障规划的通知:国办发〔2021〕36号[EB/OL].(2021-09-23)[2022-08-10] .http://www.gov.cn/zhengce/content/2021-09/29/content_5639967.htm.
[7] 谈在祥,范舜.药品"4+7"带量集中采购背景下医药企业的挑战与应对[J].卫生经济研究, 2019,36(8):4.
[8] LAN T, GUAN L, PANG X, et al.Impact of the National Centralized Drug Procurement Policy (4+7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series[J]. Journal of Clinical Pharmacy and Therapeutics, 2021.
[9] 蒋雨彤,谈在祥.我国药品带量采购政策实施效果及其优化建议[J].中国卫生事业管理, 2022,39(4):5.
[10] 梁刚,赵福兰,周彦池,等.药品集中带量采购政策的执行问题及对策建议[J].中国药物经济学,2022,17(3):4.
[11] 乔泽林,黄哲.医疗机构应对带量采购药品供应链中断的采购策略[J].医药导报,2022, 41(2):6.
[12] 人民网.医保谈判新药入院难?专家解读如何打通“堵点”[EB/OL].(2021-04-20)[2022-08-10] .http://health.people.com.cn/n1/2021/0420/c14739-32082223.html.
